P. J. O'Dwyer

Publication List Details

Period

1992 - 2007

Number

30

Co-Authors

A phase I and pharmacokinetic study of lapatinib in combination with infusional 5-fluorouracil, leucovorin and irinotecan (2007)

Midgley, R. S., Kerr, D. J., Flaherty, K. T., Stevenson, J. P., Pratap, S. E., Koch, K. M., ...

Background: This study determined the optimally tolerated regimen (OTR) of oral lapatinib administered in combination with infusional 5-fluorouracil (5-FU), leucovorin and irinotecan (FOLFIRI) and...

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200 (2006)

Giantonio, B. J., Levy, D. E., O'Dwyer, P. J., Meropol, N. J., Catalano, P. J., Benson, A. B.

Aim: Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL. The first 20 patients received...

A phase II study of high-dose bevacizumab in combination with irinotecan, 5-fluorouracil, leucovorin, as initial therapy for advanced colorectal cancer: results from the eastern cooperative oncology group study E2200 (2006)

Giantonio, B. J., Levy, D. E., O'Dwyer, P. J., Meropol, N. J., Catalano, P. J., Benson, A. B.

Aim: Patients with untreated advanced colorectal cancer were enrolled to this single arm phase II multi-center cooperative group trial of bevacizumab combined with IFL. The first 20 patients received...

Phase I/pharmacokinetic study of the topoisomerase I inhibitor GG211 administered as a 21-day continuous infusion (1999)

Stevenson, J. P., DeMaria, D., Sludden, J., Kaye, S. B., Paz-Ares, L., Grochow, L. B., ...

Background: Preclinical results support a prolonged schedule of administration for topoisomerase I inhibitors, and we have previously demonstrated the safety and activity of the novel water-soluble...

Patient treatment on a compassionate basis: Documentation of high adverse drug reaction rate (1992)

Leyland-Jones, B., Davies, B. R., Clagett-Carr, K., Shoemaker, D., Macfarlane, D., Fortner, C., ...

The special exception mechanism was established by the Division of Cancer Treatment (DCT), National Cancer Institute (NCI), for the provision of anticancer drugs not yet approved by the Food and Drug...

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Godwin, A K, Meister, A, O'Dwyer, P J, Huang, C S, Hamilton, T C, Anderson, M E

Exposure of human ovarian tumor cell lines to cisplatin led to development of cell lines that exhibited increasing degrees of drug resistance, which were closely correlated with increase of the...

Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz.

O'Dwyer, P J, Szarka, C E, Yao, K S, Halbherr, T C, Pfeiffer, G R, Green, F, ...

Prolonged exposure to mutagenic substances is strongly associated with an individual's risk of developing colorectal cancer. Clinical investigation of oltipraz as a chemopreventive agent is supported...

Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia.

Yao, K S, Xanthoudakis, S, Curran, T, O'Dwyer, P J

Many solid tumors contain substantial fractions of hypoxic cells which are relatively resistant to both radiation therapy and certain cytotoxic drugs. We have previously shown that exposure of human...

High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis.

Godwin, A K, Meister, A, O'Dwyer, P J, Huang, C S, Hamilton, T C, Anderson, M E

Exposure of human ovarian tumor cell lines to cisplatin led to development of cell lines that exhibited increasing degrees of drug resistance, which were closely correlated with increase of the...

Activation of AP-1 and of a nuclear redox factor, Ref-1, in the response of HT29 colon cancer cells to hypoxia.

Yao, K S, Xanthoudakis, S, Curran, T, O'Dwyer, P J

Many solid tumors contain substantial fractions of hypoxic cells which are relatively resistant to both radiation therapy and certain cytotoxic drugs. We have previously shown that exposure of human...

Modulation of gene expression in subjects at risk for colorectal cancer by the chemopreventive dithiolethione oltipraz.

O'Dwyer, P J, Szarka, C E, Yao, K S, Halbherr, T C, Pfeiffer, G R, Green, F, ...

Prolonged exposure to mutagenic substances is strongly associated with an individual's risk of developing colorectal cancer. Clinical investigation of oltipraz as a chemopreventive agent is supported...

Omeprazole inhibits colorectal carcinogenesis induced by azoxymethane in rats.

Penman, I D, El-Omar, E, McGregor, J R, Hillan, K J, O'Dwyer, P J, McColl, K E

Numerous clinical and experimental studies suggest that gastrin plays an important part in the development of colorectal cancer in humans. This study was done to assess the influence of omeprazole...

Duodenocaval fistula in peptic ulceration.

Geraghty, J G, Coveney, E, Kennedy, T E, O'Dwyer, P J, Murphy, J J

Duodenocaval fistula is usually caused by abdominal trauma. We report a patient in whom it was associated with peptic ulcer.

Viable intraluminal tumour cells and local/regional tumour growth in experimental colon cancer.

O'Dwyer, P. J., Martin, E. W.

To determine if viable intraluminal tumour cells can leak through a watertight anastomosis and cause local/regional (extraluminal) tumour growth, tumour cells were introduced 2 cm proximal to a...

Influence of injection site for low-dose heparin on wound complication rates after inguinal hernia repair.

Wright, D. M., O'Dwyer, P. J., Paterson, C. R.

A high incidence of complications related to bleeding was observed after open prosthetic inguinal hernia repair. The site of injection of low-dose heparin into the abdominal wall was thought to be a...

Patient recovery following cholecystectomy through a 6 cm or 15 cm transverse subcostal incision: a prospective randomized clinical trial.

O'Dwyer, P. J., McGregor, J. R., McDermott, E. W., Murphy, J. J., O'Higgins, N. J.

The effect of incision length on patient recovery following cholecystectomy has not been investigated previously. In this study, 30 patients with symptomatic gallstones were randomized to...

Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

O'Dwyer, P. J., LaCreta, F. P., Walczak, J., Cox, T., Litwin, S., Hoffman, J. P., ...

SR2508 sensitises certain hypoxic tumor cells in vitro and in vivo to the cytotoxic action of radiation and alkylating agents. The mechanism of sensitisation may derive in part from depletion of...

Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

Eisen, T, Ahmad, T, Flaherty, K T, Gore, M, Kaye, S, Marais, R, ...

The effects of sorafenib – an oral multikinase inhibitor targeting the tumour and tumour vasculature – were evaluated in patients with advanced melanoma enrolled in a large multidisease Phase II...

Gene expression profiling of human ovarian tumours

Biade, S, Marinucci, M, Schick, J, Roberts, D, Workman, G, Sage, E H, ...

There is currently a lack of reliable diagnostic and prognostic markers for ovarian cancer. We established gene expression profiles for 120 human ovarian tumours to identify determinants of...

In vitro hypoxia-conditioned colon cancer cell lines derived from HCT116 and HT29 exhibit altered apoptosis susceptibility and a more angiogenic profile in vivo

Yao, K, Gietema, J A, Shida, S, Selvakumaran, M, Fonrose, X, Haas, N B, ...

Hypoxia is an important selective force in the clonal evolution of tumours. Through HIF-1 and other transcription factors combined with tumour-specific genetic alterations, hypoxia is a dominant...

A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

Veronese, M L, Sun, W, Giantonio, B, Berlin, J, Shults, J, Davis, L, ...

Inhibition of epidermal growth factor receptor (EGFR) signalling contributes to the therapy of colorectal cancer. Gefitinib, an oral EGFR tyrosine kinase inhibitor, shows supra-additive growth...

Identification of genes associated with platinum drug sensitivity and resistance in human ovarian cancer cells

Roberts, D, Schick, J, Conway, S, Biade, S, Laub, P B, Stevenson, J P, ...

Platinum-based chemotherapeutic regimens are ultimately unsuccessful due to intrinsic or acquired drug resistance. Understanding the molecular basis for platinum drug sensitivity/resistance is...